Dynavax Technologies マネジメント
マネジメント 基準チェック /44
Dynavax Technologiesの CEO はRyan Spencerで、 Dec2019年に任命され、 の在任期間は 4.92年です。 の年間総報酬は$ 5.81Mで、 13.1%給与と86.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.17%を直接所有しており、その価値は$ 2.85M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と6.4年です。
主要情報
Ryan Spencer
最高経営責任者
US$5.8m
報酬総額
| CEO給与比率 | 13.1% |
| CEO在任期間 | 4.9yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 6.4yrs |
経営陣の近況
Recent updates
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$20m |
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
報酬と市場: Ryanの 総報酬 ($USD 5.81M ) は、 US市場 ($USD 5.50M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Ryanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Ryan Spencer (46 yo)
4.9yrs
在職期間
US$5,810,736
報酬
Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporation since December 16...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$5.81m | 0.17% $ 2.9m | |
| President & COO | 11.7yrs | US$2.99m | 0.024% $ 396.6k | |
| Senior VP & CFO | 3.7yrs | US$2.07m | 0.0059% $ 95.5k | |
| Chief Medical Officer and Senior VP of Clinical Development | 11.3yrs | US$1.88m | 0.049% $ 798.0k | |
| Chief Accounting Officer & Controller | 4.5yrs | データなし | データなし | |
| Senior VP & Chief Human Resources Officer | 5.8yrs | データなし | データなし | |
| VP of Investor Relations & Corporate Communications | 1.8yrs | データなし | データなし | |
| Senior VP & General Counsel | 3.4yrs | データなし | データなし | |
| Senior VP & Chief Commercial Officer | no data | データなし | データなし | |
| Senior Vice President of Vaccine Research | 3.8yrs | データなし | データなし | |
| VP, Site Head & MD for Dynavax GmbH | 3.8yrs | データなし | データなし | |
| Senior Vice President of Technical Operations | 3.8yrs | データなし | データなし |
3.8yrs
平均在職期間
59.5yo
平均年齢
経験豊富な経営陣: DVAXの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$5.81m | 0.17% $ 2.9m | |
| Independent Director | 18.3yrs | US$298.73k | 0.021% $ 344.5k | |
| Independent Director | 14.3yrs | US$290.73k | 0.0011% $ 18.6k | |
| Independent Director | 15yrs | US$278.73k | 0.016% $ 258.8k | |
| Member of Scientific Advisory Board | 1.8yrs | US$1.83m | データなし | |
| Member of Scientific Advisory Board | 6.4yrs | データなし | データなし | |
| Independent Director | 4.3yrs | US$293.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.4yrs | US$20.00k | データなし | |
| Independent Chairman of the Board | 3.1yrs | US$323.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.4yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6.4yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6.4yrs | データなし | データなし |
6.4yrs
平均在職期間
73.5yo
平均年齢
経験豊富なボード: DVAXの 取締役会 は 経験豊富 であると考えられます ( 6.4年の平均在任期間)。